- Home
- PRPL vs IMUX Comparison
PRPL vs IMUX Comparison
Compare PRPL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- IMUX
- Stock Information
- Founded
- PRPL 2010
- IMUX 2016
- Country
- PRPL United States
- IMUX United States
- Employees
- PRPL N/A
- IMUX N/A
- Industry
- PRPL Home Furnishings
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- IMUX Health Care
- Exchange
- PRPL Nasdaq
- IMUX Nasdaq
- Market Cap
- PRPL 90.3M
- IMUX 102.2M
- IPO Year
- PRPL N/A
- IMUX N/A
- Fundamental
- Price
- PRPL $0.66
- IMUX $1.12
- Analyst Decision
- PRPL Buy
- IMUX Strong Buy
- Analyst Count
- PRPL 3
- IMUX 6
- Target Price
- PRPL $1.70
- IMUX $12.67
- AVG Volume (30 Days)
- PRPL 403.9K
- IMUX 904.4K
- Earning Date
- PRPL 03-13-2025
- IMUX 05-07-2025
- Dividend Yield
- PRPL N/A
- IMUX N/A
- EPS Growth
- PRPL N/A
- IMUX N/A
- EPS
- PRPL N/A
- IMUX N/A
- Revenue
- PRPL $504,838,000.00
- IMUX N/A
- Revenue This Year
- PRPL N/A
- IMUX N/A
- Revenue Next Year
- PRPL $1.83
- IMUX N/A
- P/E Ratio
- PRPL N/A
- IMUX N/A
- Revenue Growth
- PRPL N/A
- IMUX N/A
- 52 Week Low
- PRPL $0.65
- IMUX $0.92
- 52 Week High
- PRPL $2.12
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- PRPL 23.09
- IMUX 51.41
- Support Level
- PRPL $0.77
- IMUX $1.06
- Resistance Level
- PRPL $0.85
- IMUX $1.22
- Average True Range (ATR)
- PRPL 0.06
- IMUX 0.09
- MACD
- PRPL -0.02
- IMUX -0.01
- Stochastic Oscillator
- PRPL 4.60
- IMUX 37.50
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.